Memorial Health System physician Dr. Christopher Jones has outlined GLP-1 weight-loss candidacy, dosing, and side effects, citing expected losses of 10 to 25 percent across semaglutide, tirzepatide, and the investigational phase 3 peptide retatrutide. The guidance lands as the peptide class expands…
Dr. Christopher Jones, a physician at Memorial Health System, has laid out a working benchmark for GLP-1 weight-loss medication that spans the marketed class and reaches into the pipeline. Ideal candidates, he said, are primarily patients with diabetes or a body mass index over 30. The expected results form a clean gradient: roughly 10 to 12 percent weight loss with semaglutide, 15 to 20 percent with tirzepatide, and 20 to 25 percent with retatrutide, a newer GLP-1 medication now in phase 3 clinical trials and not yet on the market. Across the class, the working expectation is 10 to 25 percent weight loss, a range wide enough that the specific molecule matters.
Dr. Jones named semaglutide, its brand form Ozempic, and tirzepatide as the commonly known drugs in the class, all carrying diabetic and weight-loss indications. The medications come in two available forms, injectable and oral, and the two routes run on different schedules. "The injectables are about once a week. The oral forms are every day." He described the choice between them as part of a deliberate, individualized process rather than a default: "Some of these are injectable, some of them are oral, and then we try to pick the best medication for the patient and use kind of a patient-centered approach."
The significance of the guidance is that it frames a fast-moving therapeutic area in practical terms. Weight-loss expectations of 20 to 25 percent, if confirmed by the phase 3 program, would put retatrutide ahead of every currently marketed GLP-1 option in Dr. Jones's account. The clinical conversation has already moved from whether the class works to which molecule, which route, and what it will cost. Because retatrutide is not yet on the market, expectations about it rest on trial evidence and clinical communication rather than prescription data, which is exactly the situation the guidance is meant to organize.
The candidacy rules are simple but conditional. "Primarily" is the operative word: Dr. Jones identified diabetes and a body mass index over 30 as the main entry criteria, leaving room for other considerations a physician might weigh. The emphasis on diabetes reflects the class's origins as glucose-lowering therapy, while the BMI threshold reflects its expansion into obesity treatment. The boundary is already being tested in the registered trial record, where several studies enroll overweight patients without type 2 diabetes who have weight-related comorbidities, a population that sits outside the simplest reading of "diabetes or BMI over 30."
On expected results, he was specific about the time frame and the ordering of the drugs. "Semaglutide typically has about a 10 to 12% weight loss after better than a year on it." Tirzepatide sits above that at 15 to 20 percent, and retatrutide above that at 20 to 25 percent. "Typically" and "better than a year" signal results that vary by patient rather than fixed guarantees. The gradient, read across all three agents, is the 10 to 25 percent range that a patient can reasonably take into a conversation with a prescriber.
Dosing and administration follow the molecule and the formulation. Injectable GLP-1 forms are taken about once a week; oral forms are taken every day. The difference is pharmacokinetic: the injectable peptides are engineered for half-lives long enough to hold steady levels over seven days, while the oral forms need a daily interval to maintain exposure. The side-effect profile, Dr. Jones said, is dominated by the gastrointestinal tract. "Acid reflux, upset stomach, maybe some nausea. Those are the common ones. The more severe ones are throwing up or diarrhea." The same mechanism that drives the weight loss drives these effects, which is why the counseling matters as much as the efficacy number. Patients, he said, should contact a provider experienced with GLP-1 medications to discuss options, costs, side effects, and administration.
Glucagon-like peptide 1, GLP-1, is an incretin hormone released from intestinal L cells after nutrient intake. It binds to GLP-1 receptors on pancreatic beta cells to potentiate glucose-dependent insulin secretion, suppresses glucagon release from alpha cells, slows gastric emptying, and acts on central appetite centers to reduce food intake. Because insulin secretion is glucose-dependent, the class carries a lower risk of hypoglycemia than older insulin secretagogues. The appetite effect is not secondary: GLP-1 receptor signaling in the hypothalamus and brainstem reduces hunger and increases satiety, which is why these molecules produce sustained weight loss rather than better glucose control alone.
The peptides in this class are engineered for durability in circulation. Semaglutide is a GLP-1 receptor agonist modified to resist enzymatic breakdown and bind albumin for a long half-life, which is what makes once-weekly dosing feasible. Tirzepatide extends the strategy with dual agonism at the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor. GIP, the other major incretin, adds its own glucose-dependent insulinotropic action and peripheral effects on adipose tissue, and a review in the tirzepatide file describes the drug as a multi-organ integrator in metabolic disease PMID 42387035 . The registered trial record on file at Peptide Atlas confirms the dual-agonist mechanism is under active investigation, including a study of combined GLP-1/GIP dual agonist therapy with structured exercise in overweight and obese individuals NCT07609160 .
The graded efficacy Dr. Jones described traces the class's evolution. GLP-1 receptor agonism in the semaglutide range yields about 10 to 12 percent weight loss after more than a year. Dual agonism in the tirzepatide range moves expectations to 15 to 20 percent. Retatrutide, the newest GLP-1 peptide in phase 3, is associated in his account with 20 to 25 percent. The side effects follow directly from the same mechanism. GLP-1 receptor activation slows gastric emptying and alters gut motility, which produces the common complaints of acid reflux, upset stomach, and nausea, and in more severe presentations, vomiting and diarrhea. The biology that produces the weight loss also produces the tolerability problem; the clinical task is to find the dose that keeps appetite suppression without tipping into gastrointestinal distress.
The clinical foundation under the guidance is visible in Peptide Atlas's registered trial records. Semaglutide appears in 668 registered clinical trials on file, with a phase breakdown of 4 phase 2 trials, 4 phase 4 trials, and 1 phase 3 trial, and 10 trials currently recruiting. Indexed PubMed papers number 197. The phase designations on file cover only a fraction of the total records; the 9 phase-labeled trials are enough to show where the class is heading. The spread extends well beyond metabolic disease. NCT07586150 LIFETRAIN tests personalized pharmaco-lifestyle interventions for severe mental illnesses including depression and bipolar disorder. NCT07430332, a phase 2 trial, tests a GLP-1 receptor agonist in stage 1 type 1 diabetes, and NCT07614412 SHIELD-T1D , also phase 2, studies the Shingrix vaccine plus a GLP-1 agonist for beta-cell preservation in recent-onset type 1 diabetes. NCT07462663 SHAPE-ENDO is a phase 4 pilot combining multimodal pre-surgical optimization with standard surgery in patients with obesity and early-stage endometrial cancer. NCT07027969, a phase 4 trial shared between the two drugs' records, examines metabolic surgery for atrial fibrillation elimination, and NCT06977438, also phase 4, targets childhood obesity with a GLP-1 plus lifestyle intervention.
Tirzepatide's file is smaller but directionally similar. Peptide Atlas has 251 registered clinical trials on file, with 5 phase 2 trials, 2 phase 4 trials, and 1 phase 3 trial, and 10 recruiting. Indexed PubMed papers number 188. Notable trials include NCT06180616, a phase 2 trial for tirzepatide in concurrent type 1 diabetes and overweight or obesity; NCT07468552, a phase 2 trial for cannabis use disorder; NCT07609160, testing dual GLP-1/GIP agonist therapy plus structured exercise in overweight and obese individuals with sarcopenia; NCT06732245, a phase 2 trial of the investigational NA-931 alongside tirzepatide; NCT07630454, a phase 4 trial examining tirzepatide for atrial fibrillation recurrence after catheter ablation in patients with obesity and heart failure with preserved ejection fraction; and NCT07027969, the shared metabolic surgery trial for atrial fibrillation elimination.
The recent literature in both files points in the same direction. Semaglutide papers include a meta-analysis of long-term safety and renal outcomes in non-diabetic obesity with chronic kidney disease or hypertension PMID 42340790 , a systematic review of weight-lowering drugs and natural female fertility PMID 42307450 , a JAMA Psychiatry randomized trial of semaglutide and effort-based decision-making in major depressive disorder PMID 42054055 , the STRIDE trial in peripheral artery disease and diabetes PMID 41780559 , and a scoping review of retinal vascular events PMID 42348481 . Tirzepatide's literature includes a real-world study in metabolic dysfunction-associated steatotic liver disease PMID 42397506 , a case report of starvation-type euglycemic ketoacidosis after unsupervised use in a non-obese, non-diabetic woman PMID 42381258 , a review of molecular mechanisms PMID 42387035 , a retrospective cohort in type 1 diabetes PMID 42387290 , and a Mayo Clinic Proceedings real-world comparison of tirzepatide and semaglutide for obesity PMID 42383938 . Third-party laboratory purity tests on file add a supply-chain data point: 8 tests for semaglutide with a highest observed purity of 99.979 percent, and 4 tests for tirzepatide with a highest observed purity of 99.864 percent.
Read together, the registration pattern is a map of the class's expansion. The phase 4 programs are post-marketing studies moving the drugs into surgical, oncologic, and cardiac populations, and the phase 2 trials in type 1 diabetes and cannabis use disorder suggest the mechanism is being tested far from its metabolic origin. One phase 4 trial, NCT07027969, appears in both files, signaling that the two marketed agents are being studied in the same surgical treatment pathway for obesity-related heart disease. The literature, meanwhile, is beginning to catalogue both benefit and risk at scale: renal and vascular outcomes, fertility, retinal events, and a metabolic emergency after unsupervised use.
The 10 to 12, 15 to 20, and 20 to 25 percent figures are Dr. Jones's clinical characterizations, not a cited clinical study, and they should be read as approximate expectations rather than trial endpoints. The qualifiers in his statements, "typically" and "better than a year," point to real variation across patients, and the retatrutide number carries the added uncertainty of a drug whose phase 3 data have not yet produced a marketed product. What the ranges do establish is a reasonable ordering of the three agents and a working sense of what a patient might expect after a year or more of treatment.
The comparative question raised by that ordering is already being studied. The tirzepatide file includes a multicenter real-world comparison of tirzepatide and semaglutide for obesity PMID 42383938 , the kind of analysis that can test an ordering like the one Dr. Jones described in actual prescribing populations. Real-world data of that sort are valuable, but they are not a substitute for randomized head-to-head evidence. What the ranges do not…
Peptides referenced: Semaglutide, Tirzepatide, Retatrutide, Glucagon, GLP-1.
Related reading: Eli Lilly vs Viking: Analyst Picks Lilly as the Better GLP-1 Stock, Durham VA joins national trial testing GLP-1 medications for alcohol use disorder, Starbucks is ending GLP-1 coverage for weight loss as employer costs climb, No Link Between GLP-1 and Hypertensive Disorders of Pregnancy.